Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Fernandez-Martinez A, Pascual T, Perrone G, Morales S, de la Haba J, González-Rivera M, Galván P, Zalfa F, Amato M, Gonzalez L, Prats M, Rojo F, Manso L, Paré L, Alonso I, Albanell J, Vivancos A, González A, Matito J, González S, Fernandez P, Adamo B, Muñoz M, Viladot M, Font C, Aya F, Vidal M, Caballero R, Carrasco E, Altomare V, Tonini G, Prat A, Martin M. Fernandez-Martinez A, et al. Among authors: gonzalez l, gonzalez rivera m, gonzalez a, gonzalez s. Oncotarget. 2017 Mar 28;8(13):21930-21937. doi: 10.18632/oncotarget.15748. Oncotarget. 2017. PMID: 28423537 Free PMC article.
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Bachelot T, et al. Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. Ann Oncol. 2019. PMID: 30796821 Free article. Clinical Trial.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Free PMC article. Clinical Trial.
Rheumatologic complications of CAR-T Cell therapy. Experience of a single center.
Gómez-Puerta JA, Monegal A, Ponce A, Peris P, Martínez-Cibrian N, Sarmiento-Monroy JC, Ortiz-Maldonado V, Triguero A, Fernández de Larrea C, Delgado J, García-Herrera A, Albero-González R, Bosch-Amate X, Español-Rego M, González A, Sanmartí R, Juan M. Gómez-Puerta JA, et al. Among authors: gonzalez a. Semin Arthritis Rheum. 2024 Dec 27;71:152610. doi: 10.1016/j.semarthrit.2024.152610. Online ahead of print. Semin Arthritis Rheum. 2024. PMID: 39754918
Basic Science and Pathogenesis.
Alhneif M, Cherukuwada L, Keating M, Corbett WC, Gonzalez AD, Ogunbona O, Bieniek KF, Seshadri S, Etemadmoghadam S, Flanagan ME. Alhneif M, et al. Among authors: gonzalez ad. Alzheimers Dement. 2024 Dec;20 Suppl 1:e092800. doi: 10.1002/alz.092800. Alzheimers Dement. 2024. PMID: 39751245
Clinical Manifestations.
Gonzalez AS, Atherton OE, Krause CA, Garcia JM, Martinez MN, Medina LD. Gonzalez AS, et al. Alzheimers Dement. 2024 Dec;20 Suppl 3:e088455. doi: 10.1002/alz.088455. Alzheimers Dement. 2024. PMID: 39750647
7,398 results